Formed in 2005 from the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas Pharma set out to do what no Japanese pharma company had done at scale: build a global brand. With approximately 80 per cent of sales generated outside Japan and operations across roughly 70 countries, the company posted record revenue of ¥1,912.3 billion ($22.9 billion) in FY2024.
Pharmaceutical mergers have a dismal track record. The combination of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical in April 2005 was supposed to be different, and it was. Yamanouchi brought Harnal (tamsulosin), one of the world’s most prescribed urology drugs, and a deep presence in the Japanese hospital market. Fujisawa brought Prograf (tacrolimus), the immunosuppressant that had become the global standard of care in organ transplantation. Together, they created Astellas Pharma, a company with two anchor franchises, a combined workforce of roughly 17,000, and a mandate to become Japan’s most international drug company.
The logic was straightforward. Neither company, alone, had the scale to sustain a global R&D pipeline. Japan’s domestic pharmaceutical market, while large, was growing slowly. The future belonged to companies that could launch simultaneously in the United States, Europe, and Asia. In FY2014, Astellas posted revenue of $11,067 million with 17,649 employees. By FY2025, the number was $22,857 million. Revenue had more than doubled, but the workforce had not: approximately 80 per cent of sales now came from outside Japan, a ratio that would have seemed implausible to either predecessor company.
PADCEV (enfortumab vedotin) is the drug that transformed Astellas from a solid mid-tier pharma company into something else entirely. It is an antibody-drug conjugate, a guided missile that delivers a cytotoxic payload directly to cancer cells expressing the protein Nectin-4. The target: urothelial cancer, the most common form of bladder cancer, a disease that had not seen a meaningful new treatment in decades.
Astellas did not develop PADCEV alone. The drug emerged from a partnership with Seagen (later acquired by Pfizer), combining Seagen’s antibody-drug conjugate technology with Astellas’s clinical development infrastructure and global commercial reach. The partnership model mattered. Astellas had the regulatory expertise to navigate FDA and EMA approvals. Seagen had the conjugation chemistry. Neither could have done it as fast alone.
The clinical data rewrote treatment guidelines. In patients with locally advanced or metastatic urothelial cancer who had failed prior therapies, PADCEV demonstrated response rates that oncologists described as unprecedented for this disease. It moved from accelerated approval to full approval, then expanded into earlier lines of therapy. By FY2024, PADCEV had become the primary growth engine driving Astellas to its record ¥1,912.3 billion in revenue. The drug did not just succeed commercially. It validated an entire therapeutic strategy: Astellas’s bet that it could compete in oncology against companies with far larger pipelines, by picking the right targets and the right partners.
Before PADCEV, before oncology became the company’s future, Astellas was built on two therapeutic pillars that generated billions in steady revenue. XTANDI (enzalutamide), a next-generation androgen receptor inhibitor for prostate cancer, became one of the best-selling oncology drugs in the world. It worked by blocking testosterone signalling in cancer cells, extending survival in men with metastatic castration-resistant prostate cancer. XTANDI gave Astellas its first real oncology franchise and proved that the company could launch and market a cancer drug globally.
The other pillar was older but no less important. Prograf (tacrolimus), inherited from Fujisawa, remained the cornerstone of transplant immunosuppression worldwide. When a patient receives a kidney, liver, or heart transplant, there is a high probability that tacrolimus is part of the anti-rejection regimen. Betanis, known as Myrbetriq (mirabegron) in some markets, addressed overactive bladder with a mechanism of action distinct from the antimuscarinics that had dominated the category for decades. Together, these products provided the cash flow that funded the R&D bets that eventually produced PADCEV.
The portfolio tells a story of deliberate sequencing. Urology and transplant immunology paid the bills. XTANDI provided the oncology beachhead. PADCEV delivered the breakthrough. Each generation of products funded the next, and by FY2024, with revenue of $10,691 million growing to $22,857 million in FY2025, the compounding was no longer incremental. It was exponential.
The challenge for any Japanese pharmaceutical company seeking global relevance is structural. Japan’s drug pricing system, while generous by historical standards, is subject to biennial price revisions that systematically erode margins. The domestic market rewards incrementalism, not risk-taking. Clinical trial protocols diverge from FDA and EMA requirements. And the cultural distance between a Tokyo headquarters and a physician in Houston or Munich is not trivial to bridge.
Astellas addressed this by doing something that many Japanese companies talk about but few execute: it relocated decision-making authority to where the patients were. The company built substantial operations in the United States and Europe, staffed with local executives who had the autonomy to make commercial and clinical decisions without routing everything through Tokyo. The result is a company headquartered in Japan that generates roughly 80 per cent of its revenue abroad. In FY2019, Astellas employed 16,243 people globally. The workforce has remained lean relative to revenue, reflecting a conscious decision to invest in pipeline rather than headcount.
The revenue trajectory tells the rest of the story. From $12,316 million in FY2016 to $8,330 million in FY2021 (a trough driven by patent expirations and currency effects), back up to $22,857 million in FY2025. The volatility is the cost of being a mid-sized company competing against firms three times its size. The record FY2024 result is the payoff.
Sources: Astellas Pharma Inc. Annual Reports and Integrated Reports FY2014 through FY2025. Company filings (Tokyo Stock Exchange). OPPI member directory.